[go: up one dir, main page]

MX384501B - Tratamiento de artritis psoriasica usando apremilast. - Google Patents

Tratamiento de artritis psoriasica usando apremilast.

Info

Publication number
MX384501B
MX384501B MX2015008685A MX2015008685A MX384501B MX 384501 B MX384501 B MX 384501B MX 2015008685 A MX2015008685 A MX 2015008685A MX 2015008685 A MX2015008685 A MX 2015008685A MX 384501 B MX384501 B MX 384501B
Authority
MX
Mexico
Prior art keywords
apremilast
psoriatic arthritis
treatment
methods
managing
Prior art date
Application number
MX2015008685A
Other languages
English (en)
Other versions
MX2015008685A (es
Inventor
Robert Day
Original Assignee
Amgen Europe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX384501(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Europe Gmbh filed Critical Amgen Europe Gmbh
Publication of MX2015008685A publication Critical patent/MX2015008685A/es
Publication of MX384501B publication Critical patent/MX384501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Se describen métodos de tratamiento, manejo o prevención de artritis psoriásica. Los métodos específicos abarcan la administración de apremilast, solo o en combinación con un segundo agente activo.
MX2015008685A 2013-03-14 2014-03-13 Tratamiento de artritis psoriasica usando apremilast. MX384501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782880P 2013-03-14 2013-03-14
PCT/US2014/025171 WO2014151180A1 (en) 2013-03-14 2014-03-13 Treatment of psoriatic arthritis using apremilast

Publications (2)

Publication Number Publication Date
MX2015008685A MX2015008685A (es) 2015-10-05
MX384501B true MX384501B (es) 2025-03-14

Family

ID=50549444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008685A MX384501B (es) 2013-03-14 2014-03-13 Tratamiento de artritis psoriasica usando apremilast.

Country Status (10)

Country Link
US (1) US9872854B2 (es)
KR (1) KR20150126618A (es)
CN (1) CN105050624A (es)
AU (1) AU2014235273A1 (es)
BR (1) BR112015020584A2 (es)
HK (1) HK1215671A1 (es)
IL (1) IL239499A0 (es)
MX (1) MX384501B (es)
NZ (1) NZ628320A (es)
WO (1) WO2014151180A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003038A (es) 2006-09-26 2009-04-15 Celgene Corp Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
UA113512C2 (xx) 2011-03-11 2017-02-10 Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування
ES2814952T3 (es) 2012-09-04 2021-03-29 Celgene Corp Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP3188745A1 (en) * 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
CN105588886B (zh) * 2014-11-18 2020-01-31 重庆医药工业研究院有限责任公司 一种采用液相色谱法测定阿普斯特及其制剂中杂质的方法
CN104458961A (zh) * 2014-12-11 2015-03-25 南京艾德凯腾生物医药有限责任公司 阿普斯特有关物质检测方法
WO2016146990A1 (en) * 2015-03-19 2016-09-22 Cipla Limited Improved process for the preparation of apremilast
CN106727344A (zh) * 2015-11-19 2017-05-31 常州爱诺新睿医药技术有限公司 一种无定型阿普斯特的固体分散体及其制备方法
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105935350B (zh) * 2015-12-18 2018-11-16 重庆两江药物研发中心有限公司 一种阿普斯特缓释植入剂及其制备方法
US20200170999A1 (en) * 2015-12-24 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Apremilast sustained release preparation
CN108181401B (zh) * 2018-01-26 2020-07-31 华侨大学 一种阿普斯特片有效成分的含量测定方法
CN109568302B (zh) * 2018-11-01 2021-07-16 郑州大学第一附属医院 一种治疗晚期肝癌的药物复合物及其应用
KR20220002488A (ko) * 2019-04-30 2022-01-06 셀진 코포레이션 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
WO2021207305A1 (en) * 2020-04-08 2021-10-14 Nostrum Pharmaceuticals, Llc Compositions and methods using interferon for treating viral respiratory infections
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
EP4452261A4 (en) * 2021-12-23 2025-11-05 Amgen Inc APREMILAST ORAL SUSPENSION
CN116019762B (zh) * 2022-09-19 2024-06-07 厦门大学 一种用于治疗银屑病的药物组合物、制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
BRPI0519030A2 (pt) 2004-12-13 2008-12-23 Celgene Corp mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
MX2010007833A (es) * 2008-01-18 2010-08-11 Oxagen Ltd Compuestos que tienen actividad antagonista de crth2.
MX2010010334A (es) 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2010030345A2 (en) 2008-09-10 2010-03-18 Celgene Corporation Processes for the preparation of aminosulfone compounds
US20140004182A1 (en) * 2009-11-19 2014-01-02 Jerome B. Zeldis Methods for the treatment of sarcoidosis

Also Published As

Publication number Publication date
MX2015008685A (es) 2015-10-05
IL239499A0 (en) 2015-08-31
BR112015020584A2 (pt) 2017-07-18
WO2014151180A1 (en) 2014-09-25
AU2014235273A2 (en) 2015-07-23
CN105050624A (zh) 2015-11-11
NZ628320A (en) 2017-04-28
US20140301980A1 (en) 2014-10-09
US9872854B2 (en) 2018-01-23
AU2014235273A1 (en) 2015-07-09
KR20150126618A (ko) 2015-11-12
HK1215671A1 (zh) 2016-09-09
US20150174100A2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
MX384501B (es) Tratamiento de artritis psoriasica usando apremilast.
IL260852B (en) Methods, devices and systems for pulmonary delivery of active agents
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2016002971A1 (es) Combinación.
MX378273B (es) Compuestos activos hacia bromodominios.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
SG10201806787VA (en) Modulators of complement factor b
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201400178A1 (ru) Лечение рака молочной железы
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
UY36075A (es) Derivados de tubulisina
MX2015010077A (es) Terapia de combinacion para el tratamiento de neumonia nosocomial.
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CR20160136A (es) Compuestos heterocíclicos
CR20140367A (es) Inhibidores de iap
MX2016014384A (es) Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
MX386151B (es) Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple.
EA201690445A1 (ru) Лечение рака